- Home
- USIO vs ANTX Comparison
USIO vs ANTX Comparison
Compare USIO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- ANTX
- Stock Information
- Founded
- USIO 1998
- ANTX 2017
- Country
- USIO United States
- ANTX United States
- Employees
- USIO N/A
- ANTX 36
- Industry
- USIO Investment Bankers/Brokers/Service
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- ANTX Health Care
- Exchange
- USIO Nasdaq
- ANTX Nasdaq
- Market Cap
- USIO 36.6M
- ANTX 38.5M
- IPO Year
- USIO N/A
- ANTX 2022
- Fundamental
- Price
- USIO $1.52
- ANTX $1.26
- Analyst Decision
- USIO Strong Buy
- ANTX Buy
- Analyst Count
- USIO 2
- ANTX 4
- Target Price
- USIO $5.00
- ANTX $3.50
- AVG Volume (30 Days)
- USIO 120.6K
- ANTX 79.8K
- Earning Date
- USIO 05-14-2025
- ANTX 05-13-2025
- Dividend Yield
- USIO N/A
- ANTX N/A
- EPS Growth
- USIO N/A
- ANTX N/A
- EPS
- USIO 0.12
- ANTX N/A
- Revenue
- USIO $82,931,840.00
- ANTX N/A
- Revenue This Year
- USIO $16.14
- ANTX N/A
- Revenue Next Year
- USIO $13.51
- ANTX N/A
- P/E Ratio
- USIO $12.67
- ANTX N/A
- Revenue Growth
- USIO N/A
- ANTX N/A
- 52 Week Low
- USIO $1.24
- ANTX $0.87
- 52 Week High
- USIO $2.92
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- USIO 52.89
- ANTX 44.61
- Support Level
- USIO $1.24
- ANTX $1.18
- Resistance Level
- USIO $1.57
- ANTX $1.33
- Average True Range (ATR)
- USIO 0.11
- ANTX 0.09
- MACD
- USIO 0.02
- ANTX -0.01
- Stochastic Oscillator
- USIO 84.85
- ANTX 42.86
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.